A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

This double-blind, placebo-controlled Phase II trial (n=50) will investigate the effects of intravenous ketamine infusions on patients with depressive symptoms in the intensive care unit (ICU).

Conducted by Mayo Clinic, Florida, the study aims to evaluate the efficacy of ketamine hydrochloride compared to a placebo in treating depression. Participants, aged 18 to 99, must have been in the ICU for at least one week with a PHQ-9 score of 10 or higher and specific medical conditions. The trial will involve three consecutive days of either ketamine or placebo infusions, with assessments conducted at various intervals to measure changes in depressive symptoms.

The primary outcome measure is the change in depressive symptoms evaluated by the PHQ-9 scale. Recruitment for the study is not yet active, with an estimated study completion date of December 2024.

Topic Depression
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Mayo Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.